Know Your Investments

Your super delivers life-saving technology


Your super is working hard to give you the retirement you deserve, but it’s also helping to deliver groundbreaking technology that improves our health.  

Our investment in Nanopore Technologies is helping to revolutionise DNA and RNA sequencing. The UK company makes products that deliver real-time genetic analysis, including handheld devices that scientists can use anywhere – the lab, the field and even in space.

The products have almost endless applications and are making a big impact in healthcare, food safety and security and environmental management and conservation.

Cheap, quick problem-solving at the source

  • Human genomic testing can give insight into how a patient may respond to disease or treatment, allowing doctors to give personalised healthcare.
  • Communities can determine if water is safe to drink.
  • Farmers can identify diseases in their crops early and take action to prevent loss.
  • Public health teams can respond rapidly to infectious disease outbreaks.
  • Authorities on fishing boats can identify species and discover illegal catches.

Nanopore Technologies also played a role in combatting COVID-19. At March 2021, around a quarter of the COVID-19 sequences in the global genomic database of influenza virus platform, GISAID, were sequenced on a Nanopore device.

Our investment in Nanopore Technologies is just one example of our $3 billion investment in projects that aim to change the world for the better while delivering future investment returns for our members.  

See more on how we invest your money.

This information is general advice only and does not take into account your personal objectives, financial situation or needs. You should consider if this information is appropriate for you in light of your circumstances before acting on it. Please read the relevant Hostplus Product Disclosure Statement (PDS), available at before making a decision about Hostplus. For a description of the target market, please read the Target Market Determination (TMD), available at​​​​​​

Issued by Host-Plus Pty Limited ABN 79 008 634 704, AFSL 244392 as trustee for the Hostplus Superannuation Fund (the Fund) ABN 68 657 495 890, MySuper No 68657 495 890 198.